Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;40(2):349-356.
doi: 10.1007/s11419-022-00616-y. Epub 2022 Mar 16.

The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines

Kieran R Manchester  1 , Laura Waters  2 , Shozeb Haider  3 , Peter D Maskell  4
Affiliations

The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines

Kieran R Manchester et al. Forensic Toxicol. 2022 Jul.

Abstract

Purpose: The number of benzodiazepines appearing as new psychoactive substances (NPS) is continually increasing. Information about the pharmacological parameters of these compounds is required to fully understand their potential effects and harms. One parameter that has yet to be described is the blood-to-plasma ratio. Knowledge of the pharmacodynamics of designer benzodiazepines is also important, and the use of quantitative structure-activity relationship (QSAR) modelling provides a fast and inexpensive method of predicting binding affinity to the GABAA receptor.

Methods: In this work, the blood-to-plasma ratios for six designer benzodiazepines (deschloroetizolam, diclazepam, etizolam, meclonazepam, phenazepam, and pyrazolam) were determined. A previously developed QSAR model was used to predict the binding affinity of nine designer benzodiazepines that have recently appeared.

Results: Blood-to-plasma values ranged from 0.57 for phenazepam to 1.18 to pyrazolam. Four designer benzodiazepines appearing since 2017 (fluclotizolam, difludiazepam, flualprazolam, and clobromazolam) had predicted binding affinities to the GABAA receptor that were greater than previously predicted binding affinities for other designer benzodiazepines.

Conclusions: This work highlights the diverse nature of the designer benzodiazepines and adds to our understanding of their pharmacology. The greater predicted binding affinities are a potential indication of the increasing potency of designer benzodiazepines appearing on the illicit drugs market.

Keywords: Blood-to-plasma ratio; Designer benzodiazepines; GABAA receptor; New psychoactive substances; QSAR.

PubMed Disclaimer

References

    1. López-Munoz F, Álamo C, García-García P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: Half a century of anxiolytic drugs. J Anxiety Disord. 2011;25:554–562. doi: 10.1016/j.janxdis.2011.01.002. - DOI - PubMed
    1. Riemann D, Perlis ML. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev. 2009;13:205–214. doi: 10.1016/j.smrv.2008.06.001. - DOI - PubMed
    1. Walters RJ, Hadley SH, Morris KDW, Amin J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat Neurosci. 2000;3:1274–1281. doi: 10.1038/81800. - DOI - PubMed
    1. Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. J Biol Chem. 2012;287:40224–40231. doi: 10.1074/jbc.R112.386664. - DOI - PMC - PubMed
    1. Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38:152–155. doi: 10.18773/austprescr.2015.055. - DOI - PMC - PubMed

Publication types

LinkOut - more resources